{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T22:08:32Z","timestamp":1791065312961,"version":"4.1.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.1001\/jamaneurol.2020.3780","type":"journal-article","created":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T15:11:46Z","timestamp":1602515506000},"page":"229","source":"Crossref","is-referenced-by-count":70,"title":["Association Between Apolipoprotein E \u03b52 vs \u03b54, Age, and \u03b2-Amyloid in Adults Without Cognitive Impairment"],"prefix":"10.1001","volume":"78","author":[{"given":"Philip S.","family":"Insel","sequence":"first","affiliation":[{"name":"Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden"},{"name":"Department of Psychiatry and Behavioral Sciences, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden"},{"name":"Memory Clinic, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Mattsson-Carlgren","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden"},{"name":"Department of Neurology, Sk\u00e5ne University Hospital, Lund University, Lund, Sweden"},{"name":"Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"noi200074r1","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1212\/WNL.0000000000004336","article-title":"APOE genotype and early \u00df-amyloid accumulation in older adults without dementia.","volume":"89","author":"Lim","year":"2017","journal-title":"Neurology"},{"issue":"9","key":"noi200074r2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092161","article-title":"Targeting apolipoprotein E for Alzheimer\u2019s disease: an industry perspective.","volume":"20","author":"Suidan","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"2","key":"noi200074r3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","article-title":"Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.","volume":"9","author":"Liu","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"noi200074r4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jalz.2018.02.009","article-title":"Prevalence of the apolipoprotein E e4 allele in amyloid \u00df positive subjects across the spectrum of Alzheimer\u2019s disease.","volume":"14","author":"Mattsson","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"4","key":"noi200074r5","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.neuron.2014.01.045","article-title":"ApoE and A\u00df in Alzheimer\u2019s disease: accidental encounters or partners?","volume":"81","author":"Kanekiyo","year":"2014","journal-title":"Neuron"},{"issue":"4852","key":"noi200074r6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.3283935","article-title":"Apolipoprotein E: cholesterol transport protein with expanding role in cell biology.","volume":"240","author":"Mahley","year":"1988","journal-title":"Science"},{"issue":"19","key":"noi200074r7","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"issue":"228","key":"noi200074r8","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"noi200074r9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.0387","article-title":"Association of factors with elevated amyloid burden in clinically normal older individuals.","author":"Sperling","year":"2020","journal-title":"JAMA Neurol"},{"key":"noi200074r10","author":"Johnson","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"3","key":"noi200074r11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","article-title":"Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer\u2019s disease and cognitively normal subjects.","volume":"53","author":"Joshi","year":"2012","journal-title":"J Nucl Med"},{"issue":"8","key":"noi200074r12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-\u00df plaques: a prospective cohort study.","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"issue":"8","key":"noi200074r13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","article-title":"The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline.","volume":"71","author":"Donohue","year":"2014","journal-title":"JAMA Neurol"},{"issue":"22","key":"noi200074r14","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1001\/jama.2017.6669","article-title":"Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons.","volume":"317","author":"Donohue","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"noi200074r15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1214\/ss\/1177012761","article-title":"Monotone regression splines in action.","volume":"3","author":"Ramsay","year":"1988","journal-title":"Statist Sci."},{"issue":"2","key":"noi200074r16","first-page":"65","article-title":"A simple sequentially rejective multiple test procedure.","volume":"6","author":"Holm","year":"1979","journal-title":"Scand J Statist"},{"issue":"1","key":"noi200074r17","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","article-title":"Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study.","volume":"11","author":"Reiman","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"noi200074r18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13195-017-0313-3","article-title":"Preclinical effects of APOE e4 on cerebrospinal fluid A\u00df42 concentrations.","volume":"9","author":"Lautner","year":"2017","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"noi200074r19","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1212\/WNL.0000000000007831","article-title":"Determining clinically meaningful decline in preclinical Alzheimer disease.","volume":"93","author":"Insel","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"noi200074r20","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.neurobiolaging.2014.12.008","article-title":"APOE e4 moderates amyloid-related memory decline in preclinical Alzheimer\u2019s disease.","volume":"36","author":"Lim","year":"2015","journal-title":"Neurobiol Aging"},{"key":"noi200074r21","author":"Mormino","year":"2014","journal-title":"Neurology"},{"issue":"9","key":"noi200074r22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","article-title":"Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.","volume":"15","author":"Yamazaki","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"noi200074r23","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00109-016-1427-y","article-title":"Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders.","volume":"94","author":"Mahley","year":"2016","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"noi200074r24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1212\/01.wnl.0000167544.54228.95","article-title":"Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age.","volume":"65","author":"Vinkers","year":"2005","journal-title":"Neurology"},{"issue":"9046","key":"noi200074r25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0140-6736(96)09328-2","article-title":"Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer\u2019s disease in the Rotterdam Study.","volume":"349","author":"Hofman","year":"1997","journal-title":"Lancet"},{"issue":"2","key":"noi200074r26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/archneur.60.2.185","article-title":"Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status.","volume":"60","author":"Evans","year":"2003","journal-title":"Arch Neurol"}],"container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/articlepdf\/2771412\/jamaneurology_insel_2020_oi_200074_1612851415.47529.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T15:59:31Z","timestamp":1613145571000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2771412"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2020.3780","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}